February 23-26, 2024, Washington, DC, USA

American Academy of Allergy Asthma & Immunology (AAAAI)

February 24-27, 2023, San Antonio, TX

American Academy of Allergy Asthma & Immunology (AAAAI)

February 28 – March 3, 2025, San Diego, CA, USA

American Academy of Allergy, Asthma & Immunology and World Allergy Organization (AAAAI/WAO Joint Congress 2025)

Oral icon

The impact of remibrutinib on urticaria control in patients with chronic spontaneous urticaria: Long-term results from the REMIX-1/-2 phase 3 trials

M. Metz, B. Yang, E. Boren, H. Takahashi, S. Altrichter, P. Wang, K. Lheritier, El-D. Martzloff, S. Haemmerle, S. Saini
Abstract Oral Presentation
Poster icon

Remibrutinib treatment has no clinical impact on mean blood cell counts in patients with chronic spontaneous urticaria: Pooled safety analysis from REMIX-1 and REMIX-2 studies

G. Mosnaim, H. Windom, G. Xinghua, M. Metz, S. Saini, A. Fukunaga, A. Burciu, S. Huang, K. Lheritier, H. Zouater, S. Haemmerle, A.G-Arnau
Abstract Poster
Poster icon

Prescribing patterns and treatment outcome of dermatologists and allergists for chronic spontaneous urticaria: Urticaria Voices study

J.A. Bernstein, T.A. Winders, J. McCarthy, P. Saraswat, M. Kalangara, D. Patil, N.C-Rothe, T. Raftery, K. Weller
Abstract Poster
Poster icon

Diagnostic delay and antihistamine treatment patterns of patients with chronic spontaneous urticaria (CSU): US data from the Urticaria Voices survey

J.A. Bernstein, D.D. Gardner, J. McCarthy, D. Patil, P. Saraswat, M. Kuruvilla, N.C-Rothe, T. Raftery
Abstract Poster
thumb icon

Efficacy of remibrutinib in patients with chronic spontaneous urticaria with or without prior exposure to biologics in the Phase 3 REMIX-1 and REMIX-2 studies

G. Mosnaim, A.M. Giménez-Arnau, M. Hide, M. Lebwohl, M. Maurer, M. Metz, S. Saini,
G. Sussman, S. Haemmerle, K. Lheritier, El-D. Martzloff, N. Seko, P. Wang, S. Gogate
Abstract Poster
thumb icon

Remibrutinib monotherapy reduced rescue medication in chronic spontaneous urticaria patients: Findings from a Phase 2b extension study

L. Clore, W. Carr, J. Tillinghast, V. Jain, J. Reed, P. Staubach, K. Lheritier, P. Walsh,
I. Nikolaev, S. Haemmerle, A.M. Giménez-Arnau
Abstract Poster
thumb icon

Remibrutinib treatment has no impact on mean blood cell counts in patients with chronic spontaneous urticaria: Results from Phase 2, 52-week extension study

A. Greiner, V. Jain, A.M Giménez-Arnau, J. Tillinghast, K. Lheritier, P. Walsh, S. Haemmerle, A. Zharkov, R. Snyder
Abstract Poster
thumb icon

Remibrutinib treatment did not impact mean total serum immunoglobulin levels or infection rates in patients with chronic spontaneous urticaria: Phase 2b study results

W. Carr, A.M. Giménez-Arnau, K. Lheritier, S. Haemmerle, A. Zharkov, S. Dahale,
K. Hayama, R. Snyder
Abstract Poster
thumb icon

Frequency of angioedema in chronic spontaneous urticaria patients: Report from the Urticaria Voices study

J.A. Bernstein, T.A. Winders, M-M. Balp, P. Saraswat, J. McCarthy, T. Raftery, M. Kuruvilla,
K. Weller
Abstract Poster
thumb icon

Time to relapse during treatment-free follow-up without remibrutinib in patients with chronic spontaneous urticaria: Subgroup analysis by baseline immunoglobulin-E levels and chronic urticaria index status from a Phase 2b extension study

A. Greiner, V. Jain, A.M. Giménez-Arnau, J. Tillinghast, K. Lheritier, S. Haemmerle, P. Walsh, I. Nikolaev, R. Snyder
Abstract Oral Presentation
thumb icon

Burden of angioedema among patients with chronic spontaneous urticaria in the United States

D. Patil, M-M. Balp, J. Rodrigues, R.K. Kohli, K. Krupsky, B.L. Balkaran, S. Gupta,
B.J. Williams, W. Soong
Abstract Poster
Novartis logo
Cookie Settings
© Copyright 2025 Novartis Pharma AG